Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?

Executive Summary

Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.


Related Content

Efficacy Studies Not Enough? Consider GSK's Salford Lung Study As New Model
Takeda Enlists Real World Evidence To Boost Marketed Entyvio
Real World Evidence: ‘Hot Topic’ At US FDA, But Not On Front Burner
Real-World Evidence And The Quest For European Market Access
How To Successfully Strategize Real World Evidence For Market Access
Q&A: Pfizer On Unlocking The Promise Of Real World Evidence
Q&A: Janssen on where it is heading with real world evidence
Real-World Evidence: Lessons From GSK's Salford Lung Study
FDA Moves Real-World Evidence Paradigm Forward With Draft Guidance
GSK Leads Way With Real World Data, But Others Follow


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts